For ROS1- and RET-rearranged NSCLC, specific outcome data are lacking due to smaller numbers, and whether TP53 affects the efficacy of targeted inhibitors (such as selpercatinib, pralsetinib) is still under investigation, but some early analyses indicate TP53-mutant RET+ patients have numerically shorter PFS on these drugs [60,61]. This evidence concerns the gene RET and non-small cell lung carcinoma.